Newswise — Abingdon Health are pleased to announce the CE marking and FDA registration of their newly available immunoassay reader – ADxLR5® as a Class 1 Medical Device. The ADxLR5® lateral flow device reader has been developed as a next generation technology designed to offer the user the most up to date features required for rapid testing, including a touch screen user interface, barcode sample identification ,stored calibration curve processing and wifi or wired connectivity.
The launch of the ADxLR5® will support the growth and expansion of the Abingdon Health multiple myeloma assays Seralite®– FLC serum and Seralite®– FLC urine. In addition, the ADxLR5® will be provided as an OEM reader solution for those customers wishing to have a bespoke reader developed alongside the development of lateral flow assays.
Using the company’s multi-disciplinary expertise Abingdon Health are now able to offer the complete solution to OEM customers to deliver lateral flow assays and customised state of the art readers suitable for sale in USA, European and other markets.
Fiona Kilvington, Head of Sales and Marketing, said: “The availability of the ADxLR5® Reader will provide improved connectivity and traceability features for our customers. The unique icon driven software is already providing workflow solutions for our own assays Seralite®– FLC serum and Seralite®– FLC urine. Furthermore we understand that this is an important solution for our OEM customers and will enable the development of lateral flow assays and reader solutions suitable for the USA market.”
The ADxLR5® will be showcased at the forthcoming AACC exhibition in Philadelphia on 2-4th August.
See a demonstration at AACC 2016
RSS